Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.
Br J Haematol
; 198(6): 1065-1068, 2022 09.
Article
in En
| MEDLINE
| ID: mdl-35751150
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Primary Myelofibrosis
/
Janus Kinase Inhibitors
Type of study:
Prognostic_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Limits:
Humans
Language:
En
Journal:
Br J Haematol
Year:
2022
Document type:
Article